Ronen Ben-Ami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7481508/publications.pdf

Version: 2024-02-01

136	7,225	38	80
papers	citations	h-index	g-index
139	139	139	8912 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Characteristics and recognition of early infections in patients treated with commercial antiâ€CD19 CARâ€T cells. European Journal of Haematology, 2022, 108, 52-60.	1.1	10
2	Frequency and Clinical Features of Candida Bloodstream Infection Originating in the Urinary Tract. Journal of Fungi (Basel, Switzerland), 2022, 8, 123.	1.5	3
3	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA - Journal of the American Medical Association, 2022, 327, 341.	3.8	76
4	Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study. Transplantation and Cellular Therapy, 2022, 28, 278.e1-278.e4.	0.6	6
5	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clinical Microbiology and Infection, 2022, 28, 735.e5-735.e8.	2.8	12
6	Clinical features and outcomes of bacteremic and non-bacteremic Campylobacteriosis: a case–control study. Infection, 2022, , 1.	2.3	0
7	Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers. Open Forum Infectious Diseases, 2022, 9, ofab656.	0.4	11
8	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematology,the, 2022, 9, e361-e373.	2.2	25
9	The changing landscape of azole-resistant invasive candidiasis. Clinical Microbiology and Infection, 2022, , .	2.8	1
10	Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT. Nature Communications, 2022, 13, 2463.	5.8	10
11	Invasive Fungal Diseases in Hospitalized Patients with COVID-19 in Israel: A Multicenter Cohort Study. Journal of Fungi (Basel, Switzerland), 2022, 8, 721.	1.5	0
12	Outcome of surgery for chronic suppurative otitis media with resistant Pseudomonas aeruginosa. European Archives of Oto-Rhino-Laryngology, 2021, 278, 959-964.	0.8	2
13	Impact of tolerance to fluconazole on treatment response in <i>Candida albicans</i> bloodstream infection. Mycoses, 2021, 64, 78-85.	1.8	29
14	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet, The, 2021, 397, 499-509.	6.3	119
15	Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open, 2021, 11, e040210.	0.8	10
16	The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature. Life, 2021, 11, 258.	1.1	14
17	Unraveling a Nosocomial Outbreak of COVID-19: The Role of Whole-Genome Sequence Analysis. Open Forum Infectious Diseases, 2021, 8, ofab120.	0.4	10
18	Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA - Journal of the American Medical Association, 2021, 325, 2457.	3.8	190

#	Article	IF	Citations
19	Resistance to Antifungal Drugs. Infectious Disease Clinics of North America, 2021, 35, 279-311.	1.9	36
20	Predictors of Early and Late Mortality for Patients with Hematologic Malignancy and Invasive Mold Disease. Journal of Fungi (Basel, Switzerland), 2021, 7, 697.	1.5	1
21	Antibiotic Use during the COVID-19 Pandemic in a Tertiary Hospital with an Ongoing Antibiotic Stewardship Program. Antibiotics, 2021, 10, 1056.	1.5	14
22	Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study. Transplantation and Cellular Therapy, 2021, 27, 788-794.	0.6	125
23	Point Mutation or Overexpression of Aspergillus fumigatus <i>cyp51B,</i> Encoding Lanosterol 14α-Sterol Demethylase, Leads to Triazole Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0125221.	1.4	13
24	An outbreak of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infections among hospital personnel with high mRNA vaccine uptake. Infection Control and Hospital Epidemiology, 2021, , 1-4.	1.0	2
25	Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1. Antimicrobial Agents and Chemotherapy, 2021, 65, e0108921.	1.4	5
26	Immunogenicity of a BNT162b2 vaccine booster in health-care workers. Lancet Microbe, The, 2021, 2, e650.	3.4	20
27	Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. New England Journal of Medicine, 2021, 385, 2140-2149.	13.9	445
28	Antibiotic Stewardship in Patients after Cellular Therapy with Febrile Neutropenia- a Single Center Prospective Unblinded Randomized Trial. Blood, 2021, 138, 747-747.	0.6	2
29	Healthcare-associated Pneumocystis jirovecii Pneumonia (PJP) Infection in HIV-negative Adults: a Multicenter Study. Israel Medical Association Journal, 2021, 23, 312-317.	0.1	1
30	Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study. Clinical Microbiology and Infection, 2020, 26, 101-106.	2.8	7
31	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clinical Infectious Diseases, 2020, 70, 2270-2280.	2.9	24
32	Cat Scratch Disease Presenting as Fever of Unknown Origin Is a Unique Clinical Syndrome. Clinical Infectious Diseases, 2020, 71, 2818-2824.	2.9	12
33	Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis—authors' response. Journal of Antimicrobial Chemotherapy, 2020, 75, 3697-3698.	1.3	8
34	Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients. Pediatric Infectious Disease Journal, 2020, 39, 718-724.	1.1	20
35	Rituximab identified as an independent risk factor for severe PJP: A case-control study. PLoS ONE, 2020, 15, e0239042.	1.1	18
36	Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection. Infectious Diseases, 2020, 52, 600-602.	1.4	73

#	Article	IF	CITATIONS
37	Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope (sup) \hat{A}^{\otimes} (sup) registry and cases from the literature. Mycoses, 2020, 63, 1060-1068.	1.8	32
38	Understanding the Emergence of Multidrug-Resistant Candida: Using Whole-Genome Sequencing to Describe the Population Structure of Candida haemulonii Species Complex. Frontiers in Genetics, 2020, 11, 554.	1.1	24
39	Single Dose of Doxycycline for the Prevention of Tick-borne Relapsing Fever. Clinical Infectious Diseases, 2020, 71, 1768-1771.	2.9	9
40	Risk Factors and Outcomes of Cutibacterium acnes Postoperative Central Nervous System Infection: A Case–Control Study. World Neurosurgery, 2020, 137, e251-e256.	0.7	5
41	Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses. MBio, 2020, 11 , .	1.8	224
42	Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. Journal of Antimicrobial Chemotherapy, 2020, 75, 2307-2313.	1.3	5
43	147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial. Open Forum Infectious Diseases, 2020, 7, S203-S204.	0.4	12
44	Outbreak of West Nile Virus disease in Israel (2015): A retrospective analysis of notified cases. Travel Medicine and Infectious Disease, 2019, 28, 41-45.	1.5	10
45	Antibiotic treatment for invasive nonpregnancy-associated listeriosis and mortality: a retrospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2243-2251.	1.3	15
46	Mucormycosis of the Central Nervous System. Journal of Fungi (Basel, Switzerland), 2019, 5, 59.	1.5	78
47	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
48	Ibrutinibâ€associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and nonâ€Hodgkin lymphoma: An observational study. Mycoses, 2019, 62, 1140-1147.	1.8	57
49	Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS. Frontiers in Cellular and Infection Microbiology, 2019, 9, 20.	1.8	48
50	Chronic schistosomiasis in African immigrants in Israel. Medicine (United States), 2019, 98, e18481.	0.4	5
51	Reply to Gudiol et al. Clinical Infectious Diseases, 2019, 68, 891-891.	2.9	1
52	An Outbreak of <i>Microsporum canis</i> infection at a military base associated with stray cat exposure and personâ€toâ€person transmission. Mycoses, 2018, 61, 472-476.	1.8	18
53	Genome Sequence of a Multidrug-Resistant Candida haemulonii Isolate from a Patient with Chronic Leg Ulcers in Israel. Genome Announcements, 2018, 6, .	0.8	11
54	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clinical Microbiology and Infection, 2018, 24, 1070-1076.	2.8	58

#	Article	IF	CITATIONS
55	Extended vs Bolus Infusion of Broad-Spectrum \hat{I}^2 -Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. Clinical Infectious Diseases, 2018, 67, 1153-1160.	2.9	38
56	<i>Candida auris</i> Infection Leading to Nosocomial Transmission, Israel, 2017. Emerging Infectious Diseases, 2018, 24, 801-804.	2.0	38
57	Treatment of Invasive Candidiasis: A Narrative Review. Journal of Fungi (Basel, Switzerland), 2018, 4, 97.	1.5	68
58	Cryptococcosis as a cause of nephrotic syndrome? A case report and review of the literature. IDCases, 2018, 12, 142-148.	0.4	3
59	Phenotypic and genotypic characteristics of <i>Candida albicans</i> isolates from bloodstream and mucosal infections. Mycoses, 2017, 60, 534-545.	1.8	12
60	Long-term outcomes of inappropriate antibiotic therapy for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a retrospective cohort study. Diagnostic Microbiology and Infectious Disease, 2017, 89, 222-229.	0.8	9
61	Multidrug-Resistant <i>Candida haemulonii</i> and <i>C. auris</i> , Tel Aviv, Israel. Emerging Infectious Diseases, 2017, 23, .	2.0	224
62	Assessment of Candida auris Response to Antifungal Drugs Using Time–Kill Assays and an Animal Model. Open Forum Infectious Diseases, 2017, 4, S73-S73.	0.4	2
63	Host Factors Affect the Clinical Presentation and Biomarker Sensitivity in Patients with Invasive Pulmonary Aspergillosis. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
64	Candida haemulonii and Candida auris: Emerging Multidrug-Resistant Species With Distinct Virulence and Epidemiological Characteristics. Open Forum Infectious Diseases, 2016, 3, .	0.4	2
65	Tinea capitis outbreak among paediatric refugee population, an evolving healthcare challenge. Mycoses, 2016, 59, 553-557.	1.8	31
66	NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7. Cell Host and Microbe, 2016, 20, 527-534.	5.1	74
67	Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with <i>In Vivo</i>	1.8	61
68	Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target. PLoS Pathogens, 2016, 12, e1005479.	2.1	35
69	Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection. Clinical Microbiology and Infection, 2015, 21, 1011-1017.	2.8	27
70	Mycetoma of the Foot Caused by Madurella Mycetomatis in Immigrants from Sudan. Israel Medical Association Journal, 2015, 17, 418-20.	0.1	8
71	Effect of a ventilator-focused intervention on the rate of Acinetobacter baumannii infection among ventilated patients. American Journal of Infection Control, 2014, 42, 996-1001.	1.1	4
72	Frequency, Pattern, and Cause of Fever Following Transfemoral Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 113, 1001-1005.	0.7	12

#	Article	IF	Citations
73	The impact of new epidemiological cutoff values on Candida glabrata resistance rates and concordance between testing methods. Diagnostic Microbiology and Infectious Disease, 2014, 79, 209-213.	0.8	14
74	A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. Journal of Antimicrobial Chemotherapy, 2013, 68, iii25-iii33.	1.3	12
75	Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel. Clinical Microbiology and Infection, 2013, 19, 752-756.	2.8	16
76	Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment. Microbial Pathogenesis, 2013, 55, 16-20.	1.3	9
77	Tacrolimus Enhances the Potency of Posaconazole Against Rhizopus oryzae In Vitro and in an Experimental Model of Mucormycosis. Journal of Infectious Diseases, 2013, 207, 834-841.	1.9	55
78	Proangiogenic Growth Factors Potentiate In Situ Angiogenesis and Enhance Antifungal Drug Activity in Murine Invasive Aspergillosis. Journal of Infectious Diseases, 2013, 207, 1066-1074.	1.9	22
79	Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20â€year autopsy study. Mycoses, 2013, 56, 638-645.	1.8	198
80	Angiogenesis at the mold–host interface: a potential key to understanding and treating invasive aspergillosis. Future Microbiology, 2013, 8, 1453-1462.	1.0	16
81	Multilocus sequence typing ofCandida albicansisolates from candidemia and superficial candidiasis in Israel. Medical Mycology, 2013, 51, 755-758.	0.3	13
82	Resistance to echinocandins comes at a cost. Virulence, 2012, 3, 95-97.	1.8	40
83	Fluconazole-resistantCandida: collateral damage associated with prior antibacterial exposure?. Future Microbiology, 2012, 7, 1029-1031.	1.0	4
84	Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 2518-2523.	1.4	137
85	Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections. Immunotherapy, 2012, 4, 1869-1882.	1.0	19
86	A Nonlethal Murine Cutaneous Model of Invasive Aspergillosis. Methods in Molecular Biology, 2012, 845, 569-582.	0.4	5
87	**107 Monitoring of Innate Cellular Immune Responses in Chronic Lymphocytic Leukemia (CLL)-A Pilot Study. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S121-S122.	0.2	0
88	Innate Immunity Against Moulds: Lessons Learned from Invertebrate Models. Immunological Investigations, 2011, 40, 676-691.	1.0	4
89	<i>In vitro</i> interactions among echinocandins against <i>Aspergillus fumigatus</i> : lack of concordance among methods. Medical Mycology, 2011, 49, 285-288.	0.3	8
90	Activity of Deferasirox in <i>Mucorales</i> : Influences of Species and Exogenous Iron. Antimicrobial Agents and Chemotherapy, 2011, 55, 411-413.	1.4	24

#	Article	IF	Citations
91	Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. Journal of Infectious Diseases, 2011, 204, 626-635.	1.9	124
92	Enemy of the (immunosuppressed) state: an update on the pathogenesis of <i>Aspergillus fumigatus</i> infection. British Journal of Haematology, 2010, 150, 406-417.	1.2	111
93	Antifungal Activity of Colistin against <i>Mucorales</i> Species <i>In Vitro</i> and in a Murine Model of <i>Rhizopus oryzae</i> Pulmonary Infection. Antimicrobial Agents and Chemotherapy, 2010, 54, 484-490.	1.4	56
94	Interstrain variability in the virulence of <i> Aspergillus fumigatus </i> and <i> Aspergillus terreus </i> in a <i> Toll </i> > deficient <i> Drosophila </i> fly model of invasive aspergillosis. Medical Mycology, 2010, 48, 310-317.	0.3	32
95	Cutaneous Model of Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2010, 54, 1848-1854.	1.4	31
96	<i>Toll</i> -deficient Drosophila are resistant to infection by Pneumocystis spp.: additional evidence of specificity to mammalian hosts. Virulence, 2010, 1, 523-525.	1.8	6
97	Characterization of a 5-azacytidine-induced developmental <i>Aspergillus fumigatus</i> Virulence, 2010, 1, 164-173.	1.8	19
98	Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis. Diagnostic Microbiology and Infectious Disease, 2010, 66, 200-203.	0.8	11
99	Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Medical Mycology, 2010, 48, 1-9.	0.3	17
100	Phaeohyphomycosis in a Tertiary Care Cancer Center. Clinical Infectious Diseases, 2009, 48, 1033-1041.	2.9	116
101	Increased Virulence of Zygomycetes Organisms Following Exposure to Voriconazole: A Study Involving Fly and Murine Models of Zygomycosis. Journal of Infectious Diseases, 2009, 199, 1399-1406.	1.9	117
102	Culture Medium Composition Affects the Lethality of <i>Cunninghamella bertholletiae</i> in a Fly Model of Mucormycosis. Antimicrobial Agents and Chemotherapy, 2009, 53, 4569-4569.	1.4	11
103	Increased strength of erythrocyte aggregates in blood of patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2009, 15, 707-713.	0.9	14
104	Immunomodulating effects of antifungal therapy. Current Fungal Infection Reports, 2009, 3, 243-250.	0.9	3
105	A clinicopathological study of pulmonary mucormycosis in cancer patients: Extensive angioinvasion but limited inflammatory response. Journal of Infection, 2009, 59, 134-138.	1.7	88
106	C-reactive protein velocity to distinguish febrile bacterial infections from non-bacterial febrile illnesses in the emergency department. Critical Care, 2009, 13, R50.	2.5	31
107	A Multinational Survey of Risk Factors for Infection with Extendedâ€Spectrum βâ€Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients. Clinical Infectious Diseases, 2009, 49, 682-690.	2.9	415
108	Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood, 2009, 114, 5393-5399.	0.6	99

#	Article	IF	CITATIONS
109	Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Current Opinion in Infectious Diseases, 2009, 22, 376-384.	1.3	31
110	Pathogenesis of Invasive Pulmonary Aspergillosis. , 2009, , 345-379.		1
111	Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. Journal of Antimicrobial Chemotherapy, 2008, 62, 539-542.	1.3	15
112	Time to Blood Culture Positivity as a Marker for Catheter-Related Candidemia. Journal of Clinical Microbiology, 2008, 46, 2222-2226.	1.8	73
113	Role of red blood cell flow behavior in hemodynamics and hemostasis. Expert Review of Cardiovascular Therapy, 2007, 5, 743-752.	0.6	80
114	Clinical and Economic Impact of Bacteremia with Extended- Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2006, 50, 1257-1262.	1.4	382
115	Influx of Extended-Spectrum Â-LactamaseProducing Enterobacteriaceae into the Hospital. Clinical Infectious Diseases, 2006, 42, 925-934.	2.9	298
116	Aggregation of red blood cells in patients with Gaucher disease. British Journal of Haematology, 2006, 134, 432-437.	1.2	19
117	Venous and arterial thrombosis following administration of intravenous immunoglobulins: reply to Feuillet and colleagues. Blood Coagulation and Fibrinolysis, 2005, 16, 619.	0.5	2
118	Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Current Opinion in Infectious Diseases, 2005, 18, 306-313.	1.3	194
119	Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagulation and Fibrinolysis, 2005, 16, 313-318.	0.5	124
120	Plasma Dependent Reduction in Red Blood Cell Aggregation After Dextran Sulfate Low-density Lipoprotein Apheresis-Implications for Rheological Studies. Therapeutic Apheresis and Dialysis, 2005, 9, 379-384.	0.4	4
121	Evaluation of an Accelerated Protocol for Detection of Extended-Spectrum \hat{l}^2 -Lactamase-Producing Gram-Negative Bacilli from Positive Blood Cultures. Journal of Clinical Microbiology, 2005, 43, 439-441.	1.8	5
122	Cat-Scratch Disease in Elderly Patients. Clinical Infectious Diseases, 2005, 41, 969-974.	2.9	53
123	Vitek 2 Automated Identification System and Kocuria kristinae. Journal of Clinical Microbiology, 2005, 43, 5832-5832.	1.8	30
124	Erroneous Reporting of Coagulase-Negative Staphylococci as Kocuria spp. by the Vitek 2 System. Journal of Clinical Microbiology, 2005, 43, 1448-1450.	1.8	46
125	Malaria in travelers returning from short organized tours to holiday resorts in Mombassa, Kenya. Israel Medical Association Journal, 2005, 7, 364-7.	0.1	9
126	Hospitalâ€Acquired Infective Endocarditis: Should the Definition be Broadened?. Clinical Infectious Diseases, 2004, 38, 843-850.	2.9	73

#	Article	IF	CITATION
127	Flow-resistant red blood cell aggregation in morbid obesity. International Journal of Obesity, 2004, 28, 1528-1534.	1.6	32
128	The degree of red blood cell aggregation on peripheral blood glass slides corresponds to inter-erythrocyte cohesive forces in laminar flow. Thrombosis Research, 2004, 114, 37-44.	0.8	23
129	Infection of a Ventriculoatrial Shunt with Phenotypically Variable Staphylococcus epidermidis Masquerading as Polymicrobial Bacteremia Due to Various Coagulase-Negative Staphylococci and Kocuria varians. Journal of Clinical Microbiology, 2003, 41, 2444-2447.	1.8	40
130	A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H2663-H2669.	1.5	72
131	Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations. Blood Coagulation and Fibrinolysis, 2002, 13, 57-59.	0.5	18
132	Successful Nonsurgical Treatment of Salmonella Infection of the Thoracic Aorta. Infectious Diseases in Clinical Practice, 2002, 11, 352-354.	0.1	0
133	Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability. Thrombosis Research, 2002, 105, 487-492.	0.8	21
134	lodide-induced sialadenitis complicating coronary angiography. Catheterization and Cardiovascular Interventions, 2002, 57, 50-53.	0.7	16
135	Cutaneous Involvement in a Rare Case of Adult Visceral Leishmaniasis Acquired in Israel. Journal of Infection, 2002, 44, 181-184.	1.7	12
136	Polymorphous ventricular tachycardia early after acute myocardial infarction. American Journal of Cardiology, 1993, 71, 745-749.	0.7	33